下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ.
综合来看,我们的结果揭示了 USP1 在 OS 中发挥作用的新分子机制,以及 ML323 作为 OS 临床治疗策略的潜在作用。
去泛素化酶(DUB)的突变和表达异常会深刻影响肿瘤进展。泛素特异性蛋白酶 1(USP1)是一种研究较充分的人类 DUB,据报道其在骨肉瘤(OS)中过表达,并与维持间充质干细胞状态相关;但 USP1 在 OS 中的潜在作用机制尚未充分阐明。本研究发现,USP1 在 OS 细胞系中与含 PDZ 结合基序的转录共激活因子(TAZ)直接相互作用。机制分析显示,USP1 抑制的抗 OS 效应部分可归因于 TAZ 稳定性下降;TAZ 核内积累减少继而降低 Hippo 信号通路下游相关基因的表达。此外,药理学抑制剂 ML323 对 USP1 的抑制产生了类似的 Hippo 通路效应,并在体外和体内抑制 OS 生长和转移。综上,本研究揭示 USP1 在 OS 中作用的新分子机制,并提示 ML323 可能成为临床治疗 OS 的策略。
Mutations and altered expression of deubiquitinating enzymes (DUBs) profoundly influence tumor progression. Ubiquitin-specific protease 1 (USP1) is a well-characterized human DUB reportedly overexpressed in and associated with maintaining the mesenchymal stem cell status of osteosarcoma (OS); however, the potential mechanisms of USP1 in OS remain poorly understood. In this study, we identified that USP1 directly interacts with Transcriptional Co-Activator With PDZ-Binding Motif (TAZ) in OS cell lines, and with mechanistic analysis indicating that the anti-OS effects of USP1 inhibition could be partially attributed to TAZ instability, with its reduced nuclear accumulation responsible for a subsequent decrease in the expression of downstream genes associated with the Hippo signaling pathway. Moreover, pharmacological inhibition USP1 by ML323 presented the similar effects on Hippo signaling pathway and suppressed OS growth and metastasis both in vitro and in vivo . Taken together, our results revealed a novel molecular mechanism underlying the function of USP1 in OS and a potential role of ML323 as a therapeutic strategy for the clinical treatment of OS.
MEMBER ACCOUNT
登录成功会直接打开下一页。